Jinling Jiang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Metabolic Reprogramming of NSUN2-Mediated m5C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-Mediated Cytotoxicity.
Journal: Cancer communications (London, England)
Published: January 11, 2026
GLUT3 drives paclitaxel resistance in peritoneal metastatic gastric cancer by promoting H3K18 lactylation-mediated MAPKAP1 transcription to suppress ferroptosis.
Journal: International journal of biological sciences
Published: December 16, 2025
A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19.
Journal: Future oncology (London, England)
Published: December 03, 2025
Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.
Journal: Frontiers in immunology
Published: August 14, 2025
The Role of NADPH Oxidase 4 in Neutrophil-Mediated Immune Escape in Gastric Cancer.
Journal: International journal of biological sciences
Published: July 18, 2025
Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.
Journal: Frontiers in immunology
Published: July 16, 2025
Landscape analysis of m5C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma.
Journal: Clinical epigenetics
Published: June 07, 2025
Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 12, 2025
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer.
Journal: Molecular cancer
Published: August 21, 2024
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors.
Journal: Experimental hematology & oncology
Published: June 24, 2024
Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.
Journal: BMC medicine
Published: June 21, 2024
Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.
Journal: European radiology
Published: November 12, 2023
Last Updated: 09/26/2026